News
Emerging technologies for low vision and blindness

In the UK almost 60 per cent of people wear glasses. Sight loss tends to become more common as we age, with over 1.2 million people living with visual impairments being around 75 or older and one in every two people aged 90 or over suffering from vision issues.
However, it’s not only the older generation who struggle with vision; over two million people are estimated to be living with lack of sight in the UK today, with one thing being certain – living with visual impairment can be incredibly challenging.
But, new technologies are emerging which are helping those affected maintain their independence and better deal with the demands of daily life. Agetech World focuses in on some of the latest innovations.
The OrCam MyEye Pro is a handy and lightweight gadget to help people with sight loss go about their daily lives. The wireless, wearable and portable device reads written information and relays it to the wearer through an earpiece, meaning trips to a restaurant, for example, no longer have to be a negative experience.
Not only is one-to-one training provided with each purchase, but the finger-sized appliance also includes facial, banknote and product recognition – users simply attach it to the side of their glasses through its magnet and let it do the talking though its built-in HD mini speaker or directly into OrCam Bluetooth Earphones – no internet connection required.
The innovative We Walk Smart Cane enhances the mobility of those who experience visual impairments to help them live a more independent life. It does this through its obstacle detection, which identifies any objects that are at the user’s chest level – an important feature during times of social distancing.
The Smart Cane also allows enables users to gain better access to amenities such as shops, restaurants, cafes and even has information on bus timetables by helping to guide the customer to the locations, which can be personalised through the handy We Walk app.
The device also includes voice activated technology and a screen which is editable to the needs of the user based on text size, screen colour and font, making it easier than ever for the visually impaired to be more independent when leaving the home.
The eSight glasses are described as a ‘life changing device for people with low vision’ – and it’s easy to understand why.
eSight can be used by people who suffer from cataracts, diabetic retinopathy, macular degeneration, ocular albinism and retinitis pigmentosa to help them build a better picture of their surroundings.
But how? Well, the electronic device stimulates nerve impulses from the remaining cells in the eye’s retina that are responsible for converting light into signals that are sent to the brain.
Using a camera, algorithms and high-resolution screens, the technology maximises visual information provided to the brain to compensate for gaps in the user’s field of vision – pretty impressive, right?
So not only does the electronic eyewear allow the user to see the faces of loved ones and enjoy hobbies like watching TV, reading and sport – but it enables the wearer to go about normal activities like cooking, shopping and travelling.
Next up, we have IrisVision with its glasses technology which enhances vision, enables users to stay connected and provides customers with training. Similar to the eSight glasses, the eyewear uses advanced technology to enable the wearer to enhance their independent daily living.
The headset supplies the user with specific modes to optimise the device for watching television, offers high-definition and auto focus with 14X magnification for distances and a bar magnifier for reading up close.
IrisVision‘s award-winning software also features voice controls, making it simple for the user to active the device’s different functions like reading mode, brightness options and zoom.
Each device comes with unlimited data and the option to connect to the Wi-Fi to enable the wearer to seek support from the IrisVision team whenever required.
Finally, we have the Wayband – a watch that helps the visually impaired get to their destination using only vibrations.
Whether going on a walk or a daily joy, the SmartWatch emits patterns of vibrations along the route to help them explore both new and old environments with confidence.
The device works by only vibrating when the user isn’t heading in the right direction. It maps out a corridor and if the user steps outside, a signal is sent to indicate they have gone off course.
The technology connects to a smartphone and uses data from GPS, magnetometer and compass senses to assist its user to navigate surroundings using the wrist signals – this means the communication isn’t compromised by surrounding noise so the user can still listen for nearby pedestrians and vehicles.
News
Gut-friendly foods may damage heart, charity warns
Wellness
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








